INTRODUCTION: Limited information on second-line treatment in patients with pancreatic adenocarcinoma is available. At time of first-line treatment failure, approximately half of the patients are candidates for further treatment. MATERIAL AND METHODS: A retrospective review of 183 patients submitted to second-line therapy has been performed to identify prognostic factors, provides useful information for patients counseling and generates hypotheses for future studies. Inclusion criteria were: cytological or histologic diagnosis of pancreatic adenocarcinoma and prior gemcitabine-including chemotherapy. Any age, performance status (PS) and chemotherapy regimen were considered. RESULTS: One hundred and eighty-three patients (106 males; 168 metastatic; median age 62 years; median PS 1; 63 submitted to prior curative surgery, 32 to prior radiotherapy) with a median previous progression-free survival (PFS) of 6.7 months were included. Median and 6-month PFS after initiation of salvage therapy were 3.0 months and 20%. Median, 1 and 2 years, overall survival after initiation of salvage therapy were 6.2 months, 17 and 4%, respectively. Previous PFS, CA19.9 levels and age independently predicted OS. CONCLUSION: Re-challenge with gemcitabine and 5-fluorouracil administration may have a role in selected patients.
INTRODUCTION: Limited information on second-line treatment in patients with pancreatic adenocarcinoma is available. At time of first-line treatment failure, approximately half of the patients are candidates for further treatment. MATERIAL AND METHODS: A retrospective review of 183 patients submitted to second-line therapy has been performed to identify prognostic factors, provides useful information for patients counseling and generates hypotheses for future studies. Inclusion criteria were: cytological or histologic diagnosis of pancreatic adenocarcinoma and prior gemcitabine-including chemotherapy. Any age, performance status (PS) and chemotherapy regimen were considered. RESULTS: One hundred and eighty-three patients (106 males; 168 metastatic; median age 62 years; median PS 1; 63 submitted to prior curative surgery, 32 to prior radiotherapy) with a median previous progression-free survival (PFS) of 6.7 months were included. Median and 6-month PFS after initiation of salvage therapy were 3.0 months and 20%. Median, 1 and 2 years, overall survival after initiation of salvage therapy were 6.2 months, 17 and 4%, respectively. Previous PFS, CA19.9 levels and age independently predicted OS. CONCLUSION: Re-challenge with gemcitabine and 5-fluorouracil administration may have a role in selected patients.
Authors: Igor A Astsaturov; Neal J Meropol; R Katherine Alpaugh; Barbara A Burtness; Jonathan D Cheng; Sue McLaughlin; André Rogatko; Zhiheng Xu; James C Watson; Louis M Weiner; Steven J Cohen Journal: Am J Clin Oncol Date: 2011-02 Impact factor: 2.339
Authors: Eileen M O'Reilly; Donna Niedzwiecki; Margaret Hall; Donna Hollis; Tanios Bekaii-Saab; Timothy Pluard; Kathe Douglas; Ghassan K Abou-Alfa; Hedy L Kindler; Richard L Schilsky; Richard M Goldberg Journal: Oncologist Date: 2010-12-10
Authors: E Gabriela Chiorean; Daniel D Von Hoff; Josep Tabernero; Robert El-Maraghi; Wen Wee Ma; Michele Reni; Marion Harris; Robert Whorf; Helen Liu; Jack Shiansong Li; Victoria Manax; Alfredo Romano; Brian Lu; David Goldstein Journal: Br J Cancer Date: 2016-06-28 Impact factor: 7.640